ߜ Arachidonic acid metabolites are believed to be important mediators of tissue injury during reperfusion after cerebral ischemia. To determine whether inhibiting the oxygen-dependent metabolism of arachidonic acid would reduce reperfusion injury, we administered the mixed cyclooxygenase-lipoxygenase inhibitor BW755C (3-amino-1-[m(trifluoromethyl)phenyl]-2-pyrazoline) near the time of reperfusion in a rat model of temporary focal ischemia. The duration of ischemia + reperfusion was 2 hours + 22 hours, 3 hours + 3 hours, or 3 hours + 21 hours. The effects of drug or saline treatment on infarct volume, blood-brain barrier permeability, and blood flow were determined. Cortical blood flow was monitored with laser Doppler flowmetry and blood-brain barrier permeability was evaluated by the Evans blue dye method. Infarct volume was determined in all groups by computerized image analysis of Nissl-stained sections. We found that BW755C treatment significantly attenuated delayed postischemic hypoperfusion in the 3 + 3 group (p Ͻ 0.05) and reduced the volume of Evans blue dye staining in the cortex (p Ͻ 0.01) and basal ganglia (p Ͻ 0.05). Hemispheric swelling was reduced in all treatment groups (p Ͻ 0.01), as was total infarct volume in the ischemic hemisphere (p Ͻ 0.05). These results support the hypothesis that arachidonic acid metabolites contribute to acute postischemic reperfusion injury and suggest that using a mixed cyclooxygenase-lipoxygenase inhibitor as an adjunct to thrombolytic or revascularization therapy could lengthen the ischemia time after which reperfusion is beneficial. monooxygenase inhibition; the agent has nonspecific antioxidant effects and may induce histamine release. 23, 35, 48 To determine if combined blockage of lipoxygenases and cyclooxygenase could reduce cerebral reperfusion injury, the effects of administering BW755C near the time of onset of reperfusion were studied in a rat model of temporary focal ischemia. 48 The effects of drug or saline treatment on infarction volume, BBB permeability, and blood flow were determined.
Materials and Methods

Animal Preparations
Sixty-six male Sprague-Dawley rats weighing between 280 and 300 g were anesthetized with 3.5% isoflurane, intubated, and then ventilated with 1.5% isoflurane in an air/oxygen mixture (90%: 10%). One femoral artery and one femoral vein were cannulated for administering drugs, determining arterial blood gases, and monitoring blood pressure. The contralateral temporalis muscle temperature and rectal temperature of the animals were maintained in the range of 37˚C to 38˚C throughout the experiments with a heating pad and a temperature-regulated heating lamp.
Focal cerebral ischemia was produced by occluding the middle cerebral artery (MCA) as described by Zea Longa, et al. 48 Under the operating microscope, the bifurcation of the common carotid artery was exposed, the external carotid artery was dissected and coagulated distally, and the internal carotid artery (ICA) was isolated and separated from the vagus nerve. Then the extracranial branch of the ICA was ligated close to its origin with a 5-0 silk suture. To block the origin of the MCA, a 3-0 monofilament nylon suture, its tip rounded by heating, was introduced into the ICA lumen through the stump of the external carotid artery and was gently advanced into the ICA to a distance of 22 mm from the common carotid artery bifurcation. The suture was withdrawn to permit reperfusion.
Experimental Protocol
Equal numbers of animals were randomly assigned to either saline control or BW755C treatment subgroups within the following ischemia + reperfusion groups: 2 hours ischemia + 22 hours reperfusion (2 + 22) (10 animals each in saline-and drug-treated subgroups), 3 hours ischemia + 3 hours reperfusion (3 + 3) (13 animals in each subgroup), or 3 hours ischemia followed by 21 hours of reperfusion (3 + 21) (10 animals in each subgroup). The agent BW755C (10 mg/kg dissolved in 0.5 ml 0.9% saline) or an equal amount of saline was infused intravenously with a microinjection pump for 20 minutes, beginning 5 minutes before the onset of reperfusion. This dose was based on previous dose-response data from studies of protection against myocardial ischemia and was also shown to be effective in a model of spinal cord injury. 16, 25, 28 Because the duration of the antiinflammatory effect of the drug is 9 hours in the rat, a second dose of BW755C or saline was infused at 6 hours after the onset of ischemia in the 2 + 22 and 3 + 21 groups. Infarct volume and hemispheric swelling were determined in all animals at sacrifice. Laser Doppler flowmetry (LDF) and Evans blue dye permeability were assessed in the 3 + 3 group.
Measurement of Regional Cortical Blood Flow
In the 3 + 3 group, regional cortical blood flow was measured by LDF (model BPM403, Vasamedics, Inc., St. Paul, MN) in six saline-and six drug-treated rats. Two burr holes, 1.5 mm in diameter, were drilled bilaterally at stereotactic coordinates Ϫ0.3 mm anteroposterior and 5 mm lateral from the bregma. Two 2-mV helium-neon laser probes, 0.45 mm in diameter, were mounted on a micromanipulator and placed 0.5 mm above the intact dura using microscopic guidance so that large vessels were avoided. The space between the dura and each probe was filled with warmed (37˚C) artificial cerebrospinal fluid to provide an optically transparent medium. Before ischemia was induced, baseline cortical blood flow was continuously measured until it remained stable for 30 minutes. Cortical blood flow was recorded every 5 minutes during the first 20 minutes of both occlusion and reperfusion, and every 20 minutes throughout the rest of the experiment.
The LDF technique for measuring cortical blood flow in the rat brain compares favorably with established methods such as [ 14 C]iodoantipyrine autoradiography and the hydrogen clearance technique. 14, 40 Laser Doppler flowmetry accurately reflects relative changes in superficial cortical blood flow, but absolute values are highly dependent on probe placement. 14, 40 The LDF values were therefore expressed as percentages of preocclusion baseline values.
Assessment of Blood-Brain Barrier Permeability
The permeability of the BBB to serum proteins was assessed in six rats from each of the two treatment subgroups in the 3 + 3 group. This time period was chosen because previous studies have shown that BBB permeability is maximum at this time and the permeability changes in the BBB are small and variable in the 3 + 21 and 2 + 22 groups. 9 Evans blue dye (0.3 ml 3%) in Krebs-Ringer solution was injected through a femoral vein catheter 1 hour before the rats were decapitated. The brains were fixed by intracardiac perfusion through the ascending aorta with heparinized 0.9% saline followed by 4% formaldehyde in a pH 7.4, 0.1 M phosphate-buffered saline solution. The brains were then removed and sliced coronally at 1, 3, 5, 7, 9, and 11 mm from the frontal pole. The slices were photographed with ASA 100 negative film, which was developed using the C41 process. The dyed areas of the cortex and the basal ganglia in each coronal section were measured with a computerized image analysis system (MCID, St. Catharines, Ontario, Canada). The abnormal permeability volume of the dye in each brain was estimated by adding the dyed areas of the six sections and multiplying the sum by the thickness of the sections (2 mm).
Histological Studies
Hemisphere Infarct Volume. The volume of infarction in the ischemic hemisphere was determined in the rats that survived until sacrifice in each of the three groups (13 in the 3 + 3 group, 14 in the 3 + 21 group, and 19 in the 2 + 22 group). The brains were rapidly removed and frozen in Ϫ30˚C 2-methylbutane, then placed in powdered dry ice. Twenty-micrometer-thick serial coronal sections were obtained every 0.4 mm from the anterior limit of the caudate to the posterior hippocampus (20 to 22 sections per brain). The sections were stained with cresyl violet for computerized image analysis of infarct volume. To minimize the influence that swelling in the infarcted brain has on quantification, the area of infarction in each section was determined by subtracting the area of normally staining brain in the ischemic hemisphere from that in the contralateral hemisphere. 42 The infarct volume was then calculated by adding the infarct areas measured in each section and multiplying the sum by the distance between sections (0.4 mm).
Hemispheric Swelling. The amount of hemispheric swelling was used as a measure of hemispheric edema. The total areas of the normal and ischemic hemispheres were determined using the imageanalysis system. The total hemispheric volume was calculated from all 20 to 22 sections as described above. The percentage of enlargement of the ischemic hemisphere was calculated by dividing the dif- ference between the ischemic and normal hemisphere volumes by the volume of the normal hemisphere.
Data Analysis
All histological analyses were performed by an individual blinded to the animal's experimental protocol. Changes in cortical blood flow between groups were analyzed using repeated-measures analysis of variance with pairwise contrasts. Differences in infarct volume, Evans blue dye volume, and hemispheric swelling between groups were examined with one-tailed t-tests. These differences were considered significant at p Ͻ 0.05. The data are reported as the mean Ϯ standard error. Differences in physiological variables were assessed using repeated-measures analysis of variance with contrasts. Fisher's exact test was used to compare differences in mortality between drug-and saline-treated groups.
Results
Physiological Characteristics
There was no significant difference in mean arterial blood pressure or blood gases observed between BW-755C-treated animals and controls (data not shown). The mortality for the 3 + 21 group was 40% for control and 20% for BW755C-treated animals. The mortality rate in the 2 + 22 group was 10% for control and 0% for BW755C-treated animals. In the 3 + 3 group, there was no mortality among drug-treated rats and 28% mortality in the control animals. None of these differences was statistically significant.
Cortical Blood Flow
The effect of BW755C on cortical blood flow during 3 hours of MCA occlusion and 3 hours of reperfusion is shown in Fig. 2 . Occlusion reduced cortical blood flow to approximately 20% of baseline in the ipsilateral cortex of rats treated with BW755C and control rats. Cortical blood flow remained at this level throughout the occlusion period, with no significant difference between the groups. When the MCA was reperfused, initial temporary hyperemia resulted (cortical blood flow increased to approximately 120% of baseline) in both groups. This cortical hyperemia lasted approximately 30 minutes in both groups, giving way to delayed hypoperfusion. Delayed hypoperfusion was significantly attenuated by BW755C; by 80 minutes of reperfusion, the BW755C-treated animals had significantly higher cortical blood flow than control animals (p Ͻ 0.01). Significant conservation of cortical blood flow by BW755C continued for the rest of the experiment.
Permeability of the Blood-Brain Barrier
The permeability of the BBB was reduced in rats treated with BW755C. The volume of Evans blue dye found in the cortex and basal ganglia was significantly less in the rats treated with BW755C than in control animals (p Ͻ 0.05; Fig. 3 ). Representative sections of the cortex and basal ganglia stained with Evans blue dye are shown in Fig. 4 .
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Treatment of reperfusion injury with BW755C 
Hemispheric Swelling
Rats treated with BW755C had significantly reduced hemispheric swelling manifested by fractional enlargement of the ischemic hemisphere in all groups (Fig. 5  upper) . These results confirm the Evans blue dye results and suggest that BW755C reduced disruption of the BBB.
Histological Studies
Total infarct volume was significantly reduced by BW755C in all groups (Fig. 5 lower) . These results indicate that BW755C treatment that is initiated at the onset of reperfusion remains effective in reducing infarction volume after 2 or 3 hours of ischemia.
Discussion
In this study we found that BW755C prevented delayed postischemic hypoperfusion after 3 hours of ischemia, reduced the extent of BBB disruption manifested by Evans blue dye permeability in the 3 + 3 group, and reduced hemispheric swelling and infarct volume in all groups.
Postischemic Hypoperfusion
Postischemic hypoperfusion may occur as a result of direct effects of vasoconstrictive compounds on vessels or as a secondary effect of reduced metabolic demand by the dying brain. The present study cannot differentiate between these mechanisms, but other studies have supported a direct role of arachidonic acid metabolites in postischemic hypoperfusion. The cyclooxygenase products, prostaglandins and thromboxane A 2 , and the lipoxygenase products, leukotrienes C 4 , D 4 , and E 4 , as well as 5-, 12-, and 15-HETE, are potent constrictors of the cerebral vessels. 18, 23, 36, 42, 46 The concentrations of these metabolites are significantly elevated in the brain after ischemia and reperfusion. 1, 3, 12, 27, 43 The time course is the same for the development of delayed postischemic hypoperfusion and for increases in metabolite concentrations, whereas delayed neuronal necrosis after ischemia occurs many hours or days after reperfusion. 12, 13 These results support those of other studies that have found that the vasoconstrictive action of arachidonic acid metabolites may be important in the development of postischemic hypoperfusion. One possible mechanism by which BW755C may reduce infarction is by improving blood flow during reperfusion by preventing vasoconstriction that is mediated by lipoxygenase and cyclooxygenase metabolites.
Disruption of the Blood-Brain Barrier
Disruption of the BBB after reperfusion may be mediated at least in part by arachidonic acid metabolites. Arachidonic acid and the lipoxygenase metabolites, leukotriene B 4 , C 4 , and E 4 , produce BBB damage in brain parenchyma. 4, 7 Leukotriene B 4 is a potent chemoattractant and may induce the infiltration of leukocytes following cerebral ischemia and reperfusion. 19 Leukocyte-mediated inflammation may be an important component of BBB degradation. 31 These results support the hypothesis that arachidonic acid metabolites may mediate increases in BBB permeability during reperfusion.
Infarct Volume
Our study shows that BW755C reduces infarct volume. Although this may be due to the drug's effect on postischemic hypoperfusion and on BBB disruption, some arachidonic acid metabolites may be important mediators of neurotoxic injury from ischemia and reperfusion. Leukotrienes and hepoxillins can induce a prolonged excitation of the Purkinje neurons.
32 Nordihydroguaiaretic acid, a lipoxygenase inhibitor, can block calcium-induced long-term potentiation in the dentate gyrus and in area CA1 of the hippocampus; it also blocks glutamateinduced neurotoxicity in vitro.
29, 44 The 12-lipoxygenase metabolites may play a role in the activation of N-methyl-D-aspartate (NMDA) receptors, probably by acting as second messengers or bioregulators of ion channels. 34, 35, 45 Furthermore, 12-HETE is the primary eicosanoid produced in neurons exposed to NMDA. 15 However, because BW755C does not block 12-lipoxygenase, these latter results suggest that the drug's mechanism of action may be unrelated to direct neuronal protection. This view is supported by the ineffectiveness of BW755C in a gerbil model of global ischemia.
30
Limitations of the Study
Many complex, interdependent pathophysiological and biochemical changes occur after ischemia. Our observation that BW755C prevents some of these pathophysiological changes does not rule out the possibility that other mechanisms could be at work. Indeed, BW755C may have nonspecific antioxidant effects not limited to the monooxygenase enzymes. 38 There are also technical limitations with our study design. First, although LDF has the advantage of providing continuous measures of blood flow, it does not provide absolute quantification. In addition, our measurements were restricted to the superficial cortex and therefore may not reflect flow in deep structures. Second, because of a high mortality rate, we did not measure infarction volume at times later than 24 hours after ischemia. Consequently, we cannot definitively exclude the possibility that the drug delays rather than prevents infarction. However, although delayed neuronal death occurs for many days after global ischemia, 13 there are no differences between infarct volumes at 24 hours, 72 hours, and 7 days after temporary focal ischemia when a correction for edema is applied. 24 Furthermore, in this model 8 the loss of glucose utilization is complete throughout the region of the MCA by 24 hours, suggesting that infarction is maximum at that time.
Conclusions
Despite its limitations, our study demonstrates that BW755C administered to rats immediately prior to the onset of reperfusion significantly attenuates postischemic cerebral hypoperfusion, limits BBB permeability, and reduces infarction volume at 24 hours, thus protecting the brain from reperfusion injury after temporary MCA occlusion. Our previous finding that infarct volume after 2 hours of ischemia is temporary/no less than that produced by permanent MCA occlusion 9 indicates that BW755C extends, to at least 3 hours, the time during which infarction may be reduced by reperfusion. Thus, treatments such as BW755C may be useful adjuncts to thrombolytic agents. In addition, such treatments may be useful to protect the brain after temporary intraoperative cerebrovascular occlusion. These results are consistent with the hypothesis that reperfusion injury may be mediated, at least in part, by arachidonic acid metabolites. 
